How many drugs treat Malignant tumor of cervix?

Drug Landscape tracks 9 marketed treatments for Malignant tumor of cervix (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/malignant-tumor-of-cervix.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Malignant tumor of cervix — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Malignant tumor of cervix (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Malignant tumor of cervix, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Libtayo	CEMIPLIMAB	Regeneron Pharmaceuticals		PD-1	2018-01-01
Nogitecan	topotecan	Novartis	topotecan	ATP-binding cassette sub-family G member 2	1996-01-01
Taxol	paclitaxel	Pfizer	Microtubule Inhibitor [EPC]	Tubulin beta-3 chain	1992-01-01
Taxol	nab-paclitaxel	Pfizer	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01
Blenoxane	BLEOMYCIN	Bristol-Myers Squibb	Cytoprotective Agent	Aspartyl/asparaginyl beta-hydroxylase	1973-01-01
Taxol	Taxol	M.D. Anderson Cancer Center		Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5
Hycamtin	Hycamtin	North Eastern German Society of Gynaecological Oncology		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 4, ATP-binding cassette sub-family G member 2
Abraxane	Abraxane	The First Affiliated Hospital with Nanjing Medical University		Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5
Taxol	Nabpaclitaxel	Pfizer	Microtubule Inhibitor	Tubulin beta-3 chain	1992-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 3 drugs in Malignant tumor of cervix
M.D. Anderson Cancer Center · 1 drug in Malignant tumor of cervix
North Eastern German Society of Gynaecological Oncology · 1 drug in Malignant tumor of cervix
Bristol-Myers Squibb · 1 drug in Malignant tumor of cervix
Regeneron Pharmaceuticals · 1 drug in Malignant tumor of cervix
The First Affiliated Hospital with Nanjing Medical University · 1 drug in Malignant tumor of cervix
Novartis · 1 drug in Malignant tumor of cervix

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Malignant tumor of cervix:

Cite this brief

Drug Landscape (2026). Malignant tumor of cervix — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/malignant-tumor-of-cervix. Accessed 2026-06-10.

Malignant tumor of cervix full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing